The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 16, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ravi Agrawal, trustee of the Ravi Agrawal Trust and a promoter of Ajanta Pharma, has disclosed both creation and release of pledges on his shares. On 9 September 2025, he released a pledge on 1,15,000 shares (0.09% of share capital) with Infina Finance Private Limited. Subsequently, on 11 September 2025, he created new pledges of 2,00,000 shares (0.16%) with HSBC Investdirect and 45,000 shares (0.04%) with Bajaj Finance Limited. The reasons cited for both creation and release is business financing / re-financing. After these transactions, the total encumbered shares held by the Ravi Agrawal Trust stand at 60,07,642 shares (4.81% of share capital), a net increase of 1,30,000 shares in pledged holdings.
The net pledge creation of 1.30 lakh shares is marginal and part of routine re-financing activity by the promoter, not an indication of distress or stake sale. Shareholders are unlikely to see any material impact on the stock from this disclosure.